Apexigen Inc.

Company Profile

Apexigen Inc. had its IPO on 2021-02-22 under the ticker symbol APGN.

The company operates in the Healthcare sector and Biotechnology industry. Apexigen Inc. has a staff strength of 20 employees.

Stock update

Shares of Apexigen Inc. opened at $0.39 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.39 - $0.39, and closed at $0.39.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of Apexigen Inc. have increased by 0%.

Apexigen Inc.'s Key Ratios

Apexigen Inc. has a market cap of $22.18 million, indicating a price to book ratio of 2.3187 and a price to sales ratio of 0.

In the last 12-months Apexigen Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-32576000. The EBITDA ratio measures Apexigen Inc.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Apexigen Inc.’s operating margin was 0% while its return on assets stood at -65.95% with a return of equity of -226.01%.

In Q4, Apexigen Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Apexigen Inc.’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.63 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Apexigen Inc.’s profitability.

Apexigen Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.1082. Its price to sales ratio in the trailing 12-months stood at 0.

Apexigen Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$22.86 million

Total Liabilities

$16.47 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Apexigen Inc. ended 2024 with $22.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $22.86 million while shareholder equity stood at $6.38 million.

Apexigen Inc. ended 2024 with $0 in deferred long-term liabilities, $16.47 million in other current liabilities, 2000.00 in common stock, $-176793000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.80 million and cash and short-term investments were $16.80 million. The company’s total short-term debt was $106,000 while long-term debt stood at $0.

Apexigen Inc.’s total current assets stands at $21.19 million while long-term investments were $0 and short-term investments were $2.00 million. Its net receivables were $0 compared to accounts payable of $5.34 million and inventory worth $0.

In 2024, Apexigen Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Apexigen Inc. paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.39

52-Week High

$31.35

52-Week Low

$0.61

Analyst Target Price

$6.13

Apexigen Inc. stock is currently trading at $0.39 per share. It touched a 52-week high of $31.35 and a 52-week low of $31.35. Analysts tracking the stock have a 12-month average target price of $6.13.

Its 50-day moving average was $0.42 and 200-day moving average was $0.83 The short ratio stood at 0.33 indicating a short percent outstanding of 0%.

Around 709% of the company’s stock are held by insiders while 1750.8% are held by institutions.